deficient rods cope, which are larger in size than cones and need 100,000,000 opsins/cell.
The unaltered insiders discussed above are altered in other cancers; thus, whether abnormal or normal activity of a particular gene contributes to tumorigenesis is context dependent. There must also be genes that are expressed in one cell, where they counter transformation, and are naturally off in a neighbor, increasing its susceptibility. Discovering the basal unaltered features of different cell types that render them more cancer prone will expand the repertoire of potential therapies. Several labs are already testing MDM2/4 therapeutics, and if thyroid hormone is required for cancer-promoting activity of THRβ2, perturbations in its transport or activation may also be helpful.
The cone phenotype of retinoblastoma suggests, but does not prove, that the disease originates from cones. Passengers disembarking from a plane wearing winter coats imply a chilly origin, but equally could signify a frigid destination. Guessing where cancer starts from its end-stage appearance is equally ambiguous. If retinoblastoma arises from cones, one would expect more tumors at the fovea, a cone-rich region located within the posterior (central) human retina. When newborn children with heterozygous loss of RB1 are tracked, nascent tumors do appear first at the posterior pole, but not preferentially at the fovea, and tumors also arise later in the periphery (B. Gallie, personal communication), which fits the posterior-anterior developmental wave rather than a cone origin. Cones in the outer retina synapse with interneurons in the inner nuclear layer. Tumors have been observed emerging here ( Figure 1C ), which may arise from displaced cones, or various interneurons or Müller glia in the inner nuclear layer. Retinoblastoma in mice also arises in the inner nuclear layer, exploiting the intrinsically high resistance of amacrine or horizontal neurons to apoptosis (Ajioka et al., 2007; Chen et al., 2004; MacPherson et al., 2004) . Emerging from one ground state and converting to another seems elaborate, but altering cell type is not onerous (induced pluripotent stem cells are a topical example), and "transformation" is cancer's defining feature. Until the early response of different human retinal cells to RB1 loss and the routes adopted during progression are understood, we remain (cones or no cones) very much in the dark. Wherever it is first employed, the cone circuitry is clearly a crucial component in retinoblastoma.
Like other breakthroughs in the study of retinoblastoma, the latest milestone has significance well beyond the eye. Normal is not the same as harmless. As genomewide sequencing projects continue onward toward the goal of uncovering all oncogenic mutations in all tumor types, the next major step will be to expose their hidden accomplices. Inactivation of mahogunin, an E3 ubiquitin ligase, causes a spongiform encephalopathy resembling prion disease. Chakrabarti and Hegde (2009) now report that prion proteins with aberrant topologies inactivate mahogunin, providing a plausible explanation for certain aspects of prion pathology.
why the central nervous system (CNS) is preferentially damaged. The relatively small amounts of PrP Sc needed to disrupt CNS function suggest that prions target highly specific weak points in the system.
The key features of nearly all prion diseases are transmissibility and a foamy pattern (spongiosis) of brain tissue that is visible on histological sections. Spongiosis is due primarily to intraneuronal vacuoles containing membrane fragments and, sometimes, degenerating organelles, but the etiology of this highly characteristic pathology is unclear. Much excitement surrounded the discovery that mutations in an E3 ubiquitin ligase called mahogunin cause similar spongiform changes in the CNS of "mahoganoid" mice (He et al., 2003) . This supported the notion that disorders of the proteasome degradation pathway may be involved in the toxicity of PrP Sc . However, recombinant prion protein does not undergo ubiquitination by mahogunin, and the potential link between mahogunin and the pathogenic prion protein has remained untested.
In this issue, Chakrabarti and Hegde (2009) report a physical interaction between mahogunin and PrP C that has acquired improper topologies. Although the bulk of PrP C is turned over via the endolysosomal system, some is degraded by the proteasome (Ma et al., 2002 and references therein) , which is the main degradation system for cytosolic proteins (Figure 1) . A minor pathogenic form of PrP called cyPrP, which lacks a secretory signal peptide and is constitutively released into the cytosol, is extremely neurotoxic to cerebellar neurons of transgenic mice (Ma et al., 2002) . The neurotoxicity of cyPrP may be more widespread than initially appreciated as transgenic mice with inducible forebrain-restricted expression of cyPrP show behavioral and neuropathological phenotypes (Wang et al., 2009) .
In previous work, Hegde and colleagues noted that cyPrP accumulates in the cytosol due to its inefficient import into the endoplasmic reticulum (ER) attributable to a weak secretory signal sequence. Indeed, transgenic mice expressing PrP with a very inefficient secretory signal exhibit a mild neurodegenerative phenotype (Rane et al., 2008) , supporting the view that the cytosolic accumulation of PrP C can be neurotoxic. However, there has been much debate as to whether the cytosolic accumulation pathway is relevant to the toxicity of naturally occurring prion infections. To some extent, this discussion reflects the fact that it is extremely difficult to detect cyPrP and hence to design an experiment that would disprove its relevance to prion diseases.
In their new work, Chakrabarti and Hegde (2009) discover a functional interaction between cyPrP and mahogunin, leading to an exciting new model for how mislocalized prion proteins can lead to neuronal damage and loss. Given that naked cyPrP is unstable unless the proteasome is inhibited pharmacologically, the authors began by developing a GFP-tagged version of cyPrP that has greatly enhanced stability. Coexpression of tagged mahogunin led to a tight association with aggregated cyPrP. Mahogunin did not aggregate with a fragment of huntingtin, a protein involved in a different type of neurodegenerative disease, suggesting that mahogunin does not bind generically to all pathogenic protein aggregates. Another putative neurotoxic PrP species, Ctm PrP, displays an atypical transmembrane topology and is also In the default pathway (black arrows), the mRNA encoding the normal cellular version of the prion protein (PrP C ; blue) is translated by ribosomes docked at the ER and then is imported cotranslationally into the ER lumen. In the ER, a GPI anchor (orange oval) is attached to the C terminus of PrP C (purple), which will tether the protein to the plasma membrane. However, some fraction of PrP misfolds within the ER and is then retrotranslocated to the cytosol (cyPrP) to be degraded by the proteasome (green arrows). PrP can also end up in the cytosol via the pre-emptive quality control pathway in which ER stress leads to a lack of cotranslational import, and secretory proteins are translated and degraded in the cytosol (green arrows). During cotranslational import, a small fraction of PrP ( Ctm PrP) adopts a transmembrane conformation with the C terminus in the ER lumen and the N terminus facing the cytosol (gray arrows).
Ctm
PrP may be retained within either the ER or the Golgi. Cytosolic PrP (cyPrP) and Ctm PrP bind tightly to mahogunin (green), an E3 ubiquitin ligase that has been implicated in mediating spongiform pathology in the mouse brain. associated with mahogunin. Lysosomal morphology was altered in the same way by loss of mahogunin and by cyPrP, suggesting a connection between these two proteins. As no substrates of mahogunin are known, the authors relied on lysosomal morphology as a surrogate of mahogunin function. Finally, the authors observed loss of mahogunin immunoreactivity and altered lysosomal morphology in the brains of mice expressing a mutant form of PrP that favors production of Ctm PrP. The finding of "bilaminar" spongiosis (a pattern of vacuolation that affects two discontinuous cortical layers) in human brain specimens rings alarm bells with any neuropathologist, as it is a harbinger of the prototypic prion disease of humans, Creutzfeldt-Jakob disease. The new study is tantalizing as it suggests that in order to decipher the molecular basis of prion toxicity we may need to enumerate and functionally assess the substrates of mahogunin. However, it will be crucial to assess whether mahogunin plays a role in mediating neurodegeneration in naturally occurring prion diseases such as Creutzfeldt-Jakob disease and in experimental models of prion infection such as transmission to mice of Rocky Mountain Laboratory (RML) scrapie prions.
Although it was the spongiosis in mahoganoid mice that flagged the prionmahogunin connection, the spongiosis phenotype raises some tough questions. Given that mahoganoid mice develop spongiosis and that both cyPrP and Ctm PrP appear to sequester mahogunin, it would be gratifying to observe spongiosis in mice overproducing cyPrP and Ctm PrP. However, although neither mouse strain is healthy, spongiform changes in brain tissue are not prominent (Ma et al., 2002; Rane et al., 2008; Stewart and Harris, 2005) . Conversely, spongiosis is a hallmark of prion infections, yet the extent to which typical prion infections lead to the generation of cyPrP or Ctm PrP is unclear, and the effect of prion infections on the cellular bioavailability of mahogunin has not been investigated. So might spongiosis be a "red-herring" phenotypic similarity in mahogunin-deficient and prion-infected mice? Investigating this issue will be important given that PrP oligomers can interfere directly with the proteolytic activity of the proteasome (Kristiansen et al., 2007) , suggesting that there are mahogunin-independent pathways of PrP Sc toxicity. Also, cyPrP interacts with the hydrophobic core of membranes implying that it could subvert the function of synaptic vesicles (Wang et al., 2006) .
Another poorly understood aspect of prion toxicity is the role of PrP C in cellular damage. We know that PrP C is generally required for PrP Sc to become neurotoxic (Brandner et al., 1996) . Furthermore, in a transgenic mouse expressing a neurotoxic PrP mutant (3AV) with enhanced transmembrane topology, coexpression of wild-type PrP C contributes to disease progression (Stewart and Harris, 2005) . However, the neurotoxicity of several other mutant forms of PrP is antagonized effectively by wild-type PrP C . Currently, there is no convincing theoretical framework (including the one sketched by Chakrabarti and Hegde) that can reconcile these observations. So how might the results of Chakrabarti and Hegde instruct our understanding of neurotoxicity in prion infections? As the authors note, there is an increase in ER stress markers during prion infection, suggesting a vicious circle: misfolded PrP generated during prion infection may escape from the ER and enter the cytosol via a pre-emptive quality control pathway described in previous work by Hegde and colleagues. This may lead to mahogunin inactivation and other untoward events including lipid membrane disruption and proteasome inhibition, which may favor the accumulation of cyPrP and prion pathogenesis.
Two key experiments are needed to directly test the relevance of the mahogunin-cyPrP connection to prion diseases. First, if cyPrP is a significant contributor to pathogenesis in the infectious forms of prion disease, one might expect prion infection to be synergistic with cyPrP. Hence, mice expressing cyPrP should experience aggravated pathogenesis after prion infection. However, transgenic cyPrP expression shortened the latency of disease by only ~15 days in mice infected with the RML prion strain (which is marginal at best) and not at all with a different strain, 22L (W. Jackson, A.D.S., and S. Lindquist, unpublished data). Second, if prion toxicity is mediated primarily by mahogunin, one might expect mahoganoid mice (which are not healthy yet live long enough for the purpose of this experiment) to become paradoxically resistant to prion infection. However, the presence of the mahoganoid mutation did not modulate the progress of RML prion infection (G. Carlson and G. Barsh, personal communication). These unpublished results suggest that the mahogunin-cyPrP connection may be less crucial for bone fide prion infection, or that mahogunin depletion might be compensated for by other mechanisms. Conversely, certain familial forms of human prion disease are associated with only small amounts of PrP Sc but with increased amounts of Ctm PrP and are more likely to fit the mechanism described by Chakrabarti and Hegde. In the long run, small molecules that target the mahogunin-cyPrP interaction may provide plausible therapeutic leads for treating the unfortunate families afflicted with these hereditary prion diseases.
